Epigral Reports Strong Q3 FY25 Earnings, Net Profit Surges 110% YoY

Ahmedabad, January 28, 2025 – Epigral Limited (NSE: EPIGRAL, BSE: 543332), formerly known as Meghmani Finechem Limited, has posted a significant increase in profitability in its Q3 FY25 financial results, driven by higher revenue and improved operational efficiency. The company also provided an update on the utilization of ₹333.05 crore raised through Qualified Institutional Placement (QIP).

Key Financial Highlights – Q3 FY25​

• Revenue from Operations: ₹645.24 crore (up 36.8% YoY).
• Total Income: ₹649.10 crore (up 37% YoY).
• EBITDA: ₹198.22 crore (up 48% YoY).
• Profit Before Tax (PBT): ₹153.53 crore (up 107% YoY).
• Net Profit (PAT): ₹103.54 crore (up 110% YoY).
• Earnings Per Share (EPS): ₹24.23 (compared to ₹11.87 in Q3 FY24).

For the nine months ended December 31, 2024 (9M FY25):

• Revenue: ₹1,922.50 crore (up 37% YoY).
• Net Profit: ₹270.08 crore (up 127% YoY).

Fund Utilization from QIP​

• Total Funds Raised: ₹333.05 crore (allotted on October 24, 2024).
• Amount Utilized (as of December 31, 2024): ₹292.72 crore.
• Breakdown:
  • ₹250 crore for debt repayment.
  • ₹4.21 crore for capital expenditure.
  • ₹31.39 crore for general corporate purposes.
  • ₹7.12 crore for issue expenses.
• Remaining Amount: Temporarily invested in mutual funds, to be used as per schedule.

Strategic Developments & Growth Plans​

1. Expansion in the Specialty Chemicals Segment:
   • Strengthening its presence in Chloro Alkali & Derivatives manufacturing.
2. Sustainable Energy Investments:
   • Partnered with ReNew Green (GJS Three) Private Limited for an 18.34 MW wind-solar hybrid power plant in Gujarat.
   • Secured exclusive rights to purchase energy for 25 years.
3. Name Change & Branding:
   • The company rebranded from Meghmani Finechem to Epigral in August 2023 to reflect its growing focus on specialty chemicals and sustainability.

Management Commentary​

Maulik Patel, Chairman & Managing Director, Epigral Limited, stated:
"Our strong financial performance and prudent capital utilization reinforce our long-term growth strategy. With robust revenue growth and profitability, we are well-positioned to capitalize on emerging opportunities in the specialty chemicals sector."

Investor Outlook​

Epigral's debt reduction strategy and operational efficiency position it for long-term growth. The company focuses on expansion, strategic investments, and sustainability initiatives to enhance shareholder value.